Systematic review of HIV drug resistance in Southeast Asia

AIDS Reviews

Volumn 15, Issue 3, 2013, Pages 162-170

  Trotter, Andrew B ^a,b   Hong, Steven Y ^a,b   Srikantiah, Padmini ^c   Abeyewickreme, Iyanthi ^d   Bertagnolio, Silvia ^d   Jordan, Michael R ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Drug resistance; Genotype; HIV; Southeast Asia

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; TENOFOVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; PRACTICE GUIDELINE; PROGRAM DEVELOPMENT; REVIEW; SEROCONVERSION; SEXUALLY TRANSMITTED DISEASE; SOUTHEAST ASIA; SYSTEMATIC REVIEW; URBAN POPULATION;

ANTI-HIV AGENTS; ASIA, SOUTHEASTERN; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PREVALENCE; PUBLIC HEALTH; REVERSE TRANSCRIPTASE INHIBITORS; SENTINEL SURVEILLANCE;

EID: 84890330441     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. World Health Organization: Regional Office for South-East Asia. HIV/AIDS in the south-east region: Progress report 2011. Available at: http://www.searo.who.int/entity/hiv/documents/hiv-aids-in-south-east-asia.pdf.
2. Joint United Nations Programme on HIV/AIDS. Together we will end AIDS. 2012. Available at: https://www.unaids.org/en/media/unaids/contentassets/ documents/epidemiology/2012/20120718-togetherwewillendaids-en.pdf.
3. World Health Organization. The treatment 2.0 framework for action: Catalysing the next phase of treatment, care and support. 2011. Available at: http://whqlibdoc.who.int/publications/2011/9789241501934-eng.pdf.
4. National AIDS Control Organization, Ministry of Health and Family Welfare. India. National guidelines on second-line ART for HIV-infected adults and adolescents. 2013.
5. National AIDS Program, Ministry of Health, Myanmar. Guidelines for the clinical management of HIV infection in adults and adolescents in Myanmar. 2011.
6. National AIDS/STD Program, Directorate General of Health Services, Ministry of Health and Family Welfare, Bangladesh. National guidelines of antiretroviral therapy Bangladesh. 2011.
7. National Centre for AIDS and STD Control, Ministry of Health and Population, Government of Nepal. National anti-retroviral therapy guidelines. 2012.
8. National STD/AIDS Control Programme, Ministry of Healthcare, Nutrition and UVA-Wellassa Development, Government of Sri Lanka. A guide to antiretroviral therapy. 2005.
9. Sungkanuparph S, Techasathit W, Utaipiboon C, et al. Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomedicine. 2010;4:515-28.
10. Indonesia. Kementerian Kesehatan RI. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral pada orang Dewasa dan Remaja. 2012.
11. World Health Organization. World Health Organization AIDS medicines and diagnostic service survey on ARV use, laboratory use and implementation of WHO related guidelines: Maldives. 2011.
12. World Health Organization. World Health Organization AIDS medicines and diagnostic service survey on ARV use, laboratory use and implementation of WHO related guidelines: Bhutan. 2011.
13. IV Constitutional Government Ministerio Da Saude, Republica Democratica De Timor-Leste. Opportunistic infections and antiretroviral therapy guidelines for HIV-infected adults, adolescents, children and infants in Timor-Leste. 2011.
14. Coffin J. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483.
15. World Health Organization. World Health Organization global strategy for the surveillance and monitoring of HIV drug resistance. 2012. Available at: http://apps.who.int/iris/bitstream/10665/77349/1/9789241504768-eng.pdf.
16. World Health Organization. WHO HIV drug resistance report. 2012. Available at: http://apps.who.int/iris/bitstream/10665/75183/1/9789241503938- eng.pdf.
17. Gupta R, Jordan M, Sultan B, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012;380:1250-58.
18. Jordan M. Assessments of HIV drug resistance mutations in resourcelimited settings. Clin Infect Dis. 2011;52:1058-60.
19. Pingen M, Nijhuis M, de Bruijn J, Boucher C, Wensing A. Evolutionary pathways of transmitted drug-resistant HIV-1. J Antimicrob Chemother. 2011;66:1467-80.
20. Bennett D, Camacho R, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4:e4724.
21. Duong Y, Qiu M, De A, et al. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One. 2012;7:e33328.
22. Laeyendecker O, Brookmeyer R, Cousins M, et al. HIV incidence determination in the United States: a multiassay approach. J Infect Dis. 2013;207:232-9.
23. Lodi S, Phillips A, Touloumi G, et al. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm(3): assessment of need following changes in treatment guidelines. Clin Infect Dis. 2011;53:817-25.
24. The eligibility for ART in lower income countries (eART-linc) collaboration, Wandel S, Egger M, Rangsin R, et al. Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect. 2008;84(Suppl 1):i31-6.
25. Chasombat S, Kantipong P, Pathipvanich P, et al. Thailand national surveillance system to determine the development of HIV drug resistance among ARV treated patients. XVIII International AIDS Conference; July 2010; Vienna, Austria. [Abstract THPE0427].
26. Deshpande A, Jeannot A, Schrive M, Wittkop L, Pinson P, Fleury H. Analysis of RT sequences of subtype C HIV-type 1 isolates from Indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines. AIDS Res Hum Retroviruses. 2010;26:343-50.
27. Sen S, Tripathy S, Patil A, Chimanpure V, Paranjape R. High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses. 2007;23:1303-8.
28. Sen S, Tripathy S, Chimanpure V, Patil A, Bagul R, Paranjape R. Human immunodeficiency virus type 1 drug resistance mutations in peripheral blood mononuclear cell proviral DNA among antiretroviral treatmentnaive and treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses. 2007;23:489-97.
29. Sukasem C, Churdboonchart V, Sirisidthi K, et al. Genotypic resistance mutations in treatment-naive and treatment-experienced patients under widespread use of antiretroviral drugs in Thailand: implications for further epidemiologic surveillance. Jpn J Infect Dis. 2007;60:284-9.
30. Iqbal H, Sunil S, Saravanan S, et al. High-level resistance to certain NNRTIs in association with aminoacid substitutions and K122E-K49R/KR polymorphisms among recently infected HIV patients in India. XVIII International AIDS Conference; July 2010; Vienna, Austria. [Abstract CDB0056].
31. Truong H, Lindan C, Kellogg T, et al. HIV-1 primary drug resistance and recent infection in a prospective cohort of men attending public STI clinics in Mumbai. 18th International HIV Drug Resistance Workshop; June 2009; Fort Myers, USA. [Abstract 141].
32. Thorat S, Chaturbhuj D, Hingankar N, et al. Surveillance of transmitted HIV type 1 drug resistance among HIV type 1-positive women attending an antenatal clinic in Kakinada, India. AIDS Res Hum Retroviruses. 2011;27:1291-7.
33. Ayouba A, Lien T, Nouhin J, et al. Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Cote d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study. AIDS Res Hum Retroviruses. 2009;25:1193-6.
34. Sirivichayakul S, Phanuphak P, Pankam T, O-Charoen R, Sutherland D, Ruxrungtham K. HIV drug resistance transmission threshold survey in Bangkok, Thailand. Antivir Ther. 2008;13(Suppl 2):109-13.
35. Leelawiwat W, McNicholl J, Kongpechsatit O, et al. Prevalence of HIV-1 drug resistance in recently HIV-infected men who have sex with men (MSM) in Thailand, 2007-2009: implications for PrEP. 6th International AIDS Society Conference on HIV Pathogenesis and Treatment and Prevention; July 2011; Rome, Italy. [Abstract CDB114].
36. Chonwattana W, Leelawiwat W, Kittinunvorakoon C, et al. The prevalence of transmitted HIV-1 drug resistance in recently HIV-1 infected injecting drug users in Bangkok, Thailand 2001-2004. 4th International AIDS Society Conference on HIV Pathogenesis and Treatment and Prevention; July 2007; Sydney, Australia. [Abstract TUPEB050].
37. Sirivichayakul S, O-Charoen R, Ruxrungtham K, Sutherland D, Phanuphak P. Low rate of transmission of drug resistance HIV among recent-ly- infected blood donors in Bangkok, Thailand. XVI International AIDS Conference; August 2006; Toronto, Canada. [Abstract WEPE0289].
38. Neogi U, Prarthana B, Gupta S, et al. Naturally occurring polymorphisms and primary drug resistance profile among antiretroviral-naive individuals in Bangalore, India. AIDS Res Hum Retroviruses. 2010;26:1097-101.
39. Sirivichayakul S, DeLong A, Wongkunya R, et al. Increasing HIV drug resistance among recently infected treatment-naïve MSM in Thailand: results from three years of annual surveillance. 6th International AIDS Society Conference on HIV Pathogenesis and Treatment and Prevention; July 2011; Rome, Italy. [Abstract MOPE053].
40. Tovanabutra S, Kijak G, Razak M, et al. First report on antiretroviral-drug resistance profile among recent HIV-1 seroconverter Thai intravenous drug users. XV International AIDS Conference; July 2004; Bangkok, Thailand. [Abstract WEPEB5721].
41. Chaturbhuj D, Hingankar N, Srikantiah P, et al. Transmitted HIV drug resistance among HIV-infected voluntary counseling and testing centers (VCTC) clients in Mumbai, India. AIDS Res Hum Retroviruses. 2010;26:927-32.
42. Bertagnolio S, De Luca A, Vitoria M, et al. Determinants of HIV drug resistance and public health implications in low- and middle-income countries. Antivir Ther. 2012;17:941-53.
43. HIV drug resistance [Internet]. Available at: http://www.who.int/hiv/ topics/drugresistance/en/index.html.
44. Deshpande A, Jauvin V, Magnin N, et al. Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to AR. AIDS Res Hum Retroviruses. 2007;23:335-40.
45. Kumarasamy N, Vidya Madhavan, Venkatesh K, et al. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resourcelimited settings. Clin Infect Dis. 2009;49:306-9.
46. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Chantratitra W. Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting. AIDS Patient Care STDS. 2007;21:711-14.
47. Wainberg M, Zaharatos G, Brenner B. Development of antiretroviral drug resistance. N Engl J Med. 2011;365:637-46.
48. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2010. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010. Available at http://whqlibdoc.who.int/publications/2010/9789241599764-eng.pdf.
49. Bhrushundi M, Mukhopadhyaya P, Pradhan R, et al. Pattern of drug resistance mutations in patients failing first line therapy in HIV-1 infected individuals in resource limited settings. 6th International AIDS Society Conference on HIV Pathogenesis and Treatment and Prevention; July 2011; Rome, Italy. [Abstract CDB381].
50. Gupta A, Saple D, Nadkarni G, et al. One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India. AIDS Res Hum Retroviruses. 2010;26:25-31.
51. Sungkanuparph S, Apiwattanakul N, Thititanyanont A, Chantratita W, Sirinavin S. HIV-1 Drug Resistance Mutations in Children Failing an Initial NRTI-based Regimen and Options for a Second-line Antiretroviral Regimen. 15th CROI; February 2008; Boston, USA. [Abstract 588].
52. Ekstrand M, Shet A, Chandy S, et al. Suboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India. Int Health. 2011;3:27-34.
53. Shet A, DeCosta A, Heylen E, Shastri S, Chandy S, Ekstrand M. High rates of adherence and treatment success in a public and public-private HIV clinic in India: potential benefits of standardized national care delivery systems. BMC Health Serv Res. 2011;11:277.
54. Vallabhaneni S, Chandy S, Heylen E, Ekstrand M. Reasons for and correlates of antiretroviral treatment interruptions in a cohort of patients from public and private clinics in southern India. AIDS Care. 2012;24:687-94.
55. Bangsberg D, Acosta E, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223-31.
56. Harrigan P, Hogg R, Dong W, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339-47.
57. Ramchandani S, Mehta S, Saple D, et al. Knowledge, attitudes, and practices of antiretroviral therapy among HIV-infected adults attending private and public clinics in India. AIDS Patient Care STDS. 2007;21:129-42.
58. Ekstrand M, Chandy S, Gandhi M, et al. Adherence, virologic failure and major mutations - need for 2nd line HAART in India. XVII International AIDS Conference; August 2008; Mexico City, Mexico. [Abstract WEPE0040].
59. Auwanit W, Isarangkura-Na-Ayuthaya P, Kasornpikul D, Ikuta K, Sawanpanyalert P, Kameoka M. Detection of drug resistance-associated and background mutations in human immunodeficiency virus type 1 CRF01- AE protease and reverse transcriptase derived from drug treatmentnaive patients residing in central Thailand. AIDS Res Hum Retroviruses. 2009;25:625-31.
60. Sinha S, Ahmad H, Kumar H, et al. Study of prevalence and types of baseline HIV drug resistance in the antiretroviral treatment-naive HIV infected Northern India population. XVIII International AIDS Conference; July 2010; Vienna, Austria. [Abstract THPE0360].
61. Apisarnthanarak A, Mundy L. Antiretroviral drug resistance among anti-retroviral- naive individuals with HIV infection of unknown duration in Thailand. Clin Infect Dis. 2008;46:1630-1.
62. Iqbal H, Solomon S, Madhavan V, Solomon S, Balakrishnan P. Primary HIV-1 drug resistance and polymorphic patterns among injecting drug users (IDUs) in Chennai, Southern India. J Int Assoc Physicians AIDS Care. 2009;8:323-7.
63. Lall M, Gupta R, Sen S, Kapila K, Tripathy S, Paranjape R. Profile of primary resistance in HIV-1-infected treatment-naive individuals from Western India. AIDS Res Hum Retroviruses. 2008;24:987-90.
64. Nuntachit N, Chaiwarith R, Praparattanapan J, Supparatpinyo K, Sirisanthana T. Prevalence of primary HIV drug resistance in Chiang Mai University Hospital Cohort. 6th International AIDS Society Conference on HIV Pathogenesis and Treatment and Prevention; July 2011; Rome, Italy. [Abstract CDB008].
65. Potdar P, Daswani B, Rane N. Drug resistance mutations to protease and reverse transcriptase inhibitors in treatment naive HIV-1 clade C infected individuals from Mumbai, India. Int J Virology. 2011;7:13.
66. Shet A, Neogi U, Arumugam K, et al. Genetic variation and primary drug resistance mutations among children with perinatally-acquired HIV infection. 6th International AIDS Society Conference on HIV Pathogenesis and Treatment and Prevention; July 2011; Rome, Italy. [Abstract TUPE094].
67. Kandathil A, Kannangai R, Abraham O, et al. The frequency of HIV-I drug resistance mutations among treatment-naive individuals at a tertiary care centre in south India. Int J STD AIDS. 2009;20:522-6.
68. Balakrishnan P, Kumarasamy N, Kantor R, et al. HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. AIDS Res Hum Retroviruses. 2005;21:301-5.
69. Deshpande A, Recordon-Pinson P, Deshmukh R, et al. Molecular characterization of HIV type 1 isolates from untreated patients of Mumbai (Bombay), India, and detection of rare resistance mutations. AIDS Res Hum Retroviruses. 2004;20:1032-5.
70. Rajesh L, Karunaianantham R, Narayanan P, Swaminathan S. Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients. AIDS Res Hum Retroviruses. 2009;25:1179-85.
71. Soundararajan L, Karunaianandham R, Jauvin V, et al. Characterization of HIV-1 isolates from antiretroviral drug-naive children in southern India. AIDS Res Hum Retroviruses. 2007;23:1119-26.
72. Dettrairat S, Promchim C, Kunachiwa W, Kohreanudom S. HIV drug resistance testing of national access to antiretroviral program in upper Northern Thailand. XVI International AIDS Conference; August 2006; Toronto, Canada. [Abstract CDB0188].
73. Sungkanuparph S, Apiwattanakul N, Thitithanyanont A, Chantratita W, Sirinavin S. HIV-1 drug resistance mutations in children who failed nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Southeast Asian J Trop Med Public Health. 2009;40:83-8.
74. Apisarnthanarak A, Jirayasethpong T, Sa-nguansilp C, et al. Antiretroviral drug resistance among antiretroviral-naive persons with recent HIV infection in Thailand. HIV Med. 2008;9:322-5.
75. Karnkawinpong O, Akksilp S, Korianudom S. Viral load, genotypic drug resistance assay in AIDS patients treated with d4T+3TC +NVP regimen: from routine to research. XVI International AIDS Conference; August 2006; Toronto, Canada. [Abstract MOPE0306].
76. Puthanakit T, Kerr S, Bunupuradah T, et al. Slow accumulation of thymidine analog and ETR-associated mutations in NNRTI-treated children with virologic failure. 18th CROI; March 2011; Boston, USA. [Abstract A720].
77. Solomon S, Balakrishnan P, Shetty N, et al. Prevalence of treatment failure and drug resistance among treatment-experienced HIV-1-infected individuals at a tertiary HIV referral center in south India. 14th CROI; February 2007; Los Angeles, USA. [Abstract 647].
78. Vidya M, Saravanan S, Uma S, et al. Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India. Antivir Ther. 2009;14:1005-9.
79. Arora S, Gupta S, Toor J, Singla A. Drug resistance-associated genotypic alterations in the pol gene of HIV type 1 isolates in ART-naive individuals in North India. AIDS Res Hum Retroviruses. 2008;24:125-30.
80. Saini S, Bhalla P, Baveja U, Pasha ST, Dewan R. Antiretroviral resistanceassociated mutations and genomic diversity in reverse transcriptase and protease gene amoung drug-naive patients. 14th International Congress of Infectious Disease; March 2010; Miami, USA. [Abstract 55.015].